What I think it means is that if Lexaria, during their studies on nicotine funded by Altria, discovers technology which may be applicable to cannabis, then Altria's subsidiary (Cronos?) would have the right of first refusal to either license said tech. or purchase an interest in Lexaria Canpharm or both. This seems fair and reasonable as Altria is funding the research. The downside is that there is no deal pending, at least until research is more advanced.
News 
Market Data 
Discover 
